(Q43760712)

26 November 2017

0 references

Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence (English)

1 reference

26 November 2017

1 reference

S W Schalm

1

1 reference

26 November 2017

publication date

1 September 2001

1 reference

26 November 2017

published in

Journal of Hepatology

1 reference

26 November 2017

volume

35

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

419-420

1 reference

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Long term effect of alpha interferon in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

A study of the pharmacokinetic interaction between lamivudine and alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900186-6

7 January 2021

10.1016/S0168-8278(01)00186-6

Identifiers

DOI

1 reference

26 November 2017

1 reference